Abstract
Objective Transarterial radioembolization (TARE) offers a minimally invasive and safe treatment
option for primary and metastatic hepatic malignancies. The benefits of TARE are manifold
including prolonged overall survival, low associated morbidities, and improved time
to progression allowing prolonged treatment-free intervals. The rapid development
of new systemic therapies including immunotherapy has radically changed the treatment
landscape for primary and metastatic liver cancer. Given the current climate, it is
critical for interventional oncologists to understand the benefits of TARE relative
to these other therapies. Therefore, this report aims to review quality-of-life outcomes
and the cost comparisons of TARE as compared with systemic therapies.
Keywords
transarterial radioembolization - health-related quality of life - yttrium 90 - hepatocellular
carcinoma - transarterial chemoembolization - interventional radiology
